Bruker Corporation (BRKR) Declined Amid NIH Funding and Tariff Uncertainty
AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.
There's No Escaping Bruker Corporation's (NASDAQ:BRKR) Muted Revenues
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
Stifel Maintains Bruker Corp(BRKR.US) With Hold Rating, Cuts Target Price to $48
UBS Initiates Bruker Corp(BRKR.US) With Hold Rating, Announces Target Price $45
Bruker Is Maintained at Neutral by UBS
Bruker Price Target Cut to $45.00/Share From $57.00 by UBS
Express News | UBS Maintains Neutral on Bruker, Lowers Price Target to $45
Bruker Is Maintained at Overweight by Barclays
Bruker Price Target Cut to $46.00/Share From $50.00 by Barclays
Express News | Barclays Maintains Overweight on Bruker, Lowers Price Target to $46
Bruker Price Target Cut to $45.00/Share From $50.00 by Goldman Sachs
Bruker Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45
Bruker Price Target Cut to $48.00/Share From $57.00 by Stifel
Bruker Is Maintained at Hold by Stifel
Express News | Stifel Maintains Hold on Bruker, Lowers Price Target to $48
Bruker Analyst Ratings
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $45 to $61